LLY – eli lilly and company (US:NASDAQ)

News

Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win [Yahoo! Finance]
Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound [Yahoo! Finance]
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer [Yahoo! Finance]
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Novo Nordisk Stumbles as Obesity Drug Race Heats Up [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com